Stremitzer et al. evaluated immune phenotypes of CRCLM patients by analyzing the results of patients who were treated with perioperative bevacizumab-based chemotherapy and found that desmoplastic liver tumors were associated with an “inflamed” immune phenotype, shown by the presence of CD8-positive immune cells at the tumor interface and the tumor itself. The gene discussed is CD8A; the disease is neoplasm.